Trial Profile
A Multinational, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Adenosquamous carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PACTO
- 21 Sep 2023 Status changed from active, no longer recruiting to completed.
- 06 Jun 2023 Primary endpoint (Overall survival at 6 months) has not been met, according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology